ESR1 and breast cancer: To validate our results in an independent patient cohort, we turned to the transcriptomic data from the NEOAI study, a retrospective study of patients with primary ER+/HER2− breast cancer who received neoadjuvant treatment with an AI for at least 4 weeks (48, 49).